Condition
Non-Invasive Bladder Urothelial Carcinoma
Total Trials
5
Recruiting
1
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 3 (1)
Trial Status
Active Not Recruiting1
Unknown1
Not Yet Recruiting1
Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05037279Phase 3Recruiting
Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
NCT05768347Phase 1Active Not Recruiting
Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC
NCT05335512Not Yet RecruitingPrimary
Intravesical BCG: is the Urinary Bladder Ready to Receive it
NCT04617743Unknown
The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and Progression
NCT04647981CompletedPrimary
Diagnostic Performance Evaluation Study of the Xpert® Bladder Cancer Monitor Test.
Showing all 5 trials